Argenica Therapeutics Ltd (AU:AGN)
ASX:AGN
Top Page
Argenica Therapeutics Ltd
(Sydney:AGN)
Select Model
Select Model
Rating:48Neutral
Price Target:
AU$0.14
▼(-0.71% Downside)
Action:ReiteratedDate:03/24/26
The score is held back primarily by persistent losses and ongoing cash burn (and the associated funding/dilution risk), with additional pressure from weak technicals. A debt-free balance sheet and improving revenue provide some offset, but valuation remains constrained by negative earnings and no dividend.
Positive Factors
Debt-free balance sheet
A debt-free capital structure materially reduces solvency and refinancing risk over the medium term, preserving operational flexibility. For an R&D-heavy biotech this allows management to prioritise clinical milestones and partner negotiations without near-term interest obligations, improving strategic optionality while external funding is sought.
Negative Factors
Ongoing cash burn
Persistent negative operating and free cash flows mean the company cannot self-fund its R&D and operations long-term. That creates recurring financing needs, increases dilution risk, and forces management to prioritise near-term financing over optionality, weakening resilience to trial delays or slower-than-expected commercialisation.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A debt-free capital structure materially reduces solvency and refinancing risk over the medium term, preserving operational flexibility. For an R&D-heavy biotech this allows management to prioritise clinical milestones and partner negotiations without near-term interest obligations, improving strategic optionality while external funding is sought.
Read all positive factors
Argenica Therapeutics Ltd (AGN) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$18.63M
Dividend YieldN/A
Average Volume (3M)511.75K
Price to Earnings (P/E)―
Beta (1Y)1.11
Revenue GrowthN/A
EPS Growth-5.68%
CountryAU
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.03
Shares Outstanding128,456,710
10 Day Avg. Volume288,263
30 Day Avg. Volume511,745
Financial Highlights & Ratios
PEG Ratio-2.24
Price to Book (P/B)13.39
Price to Sales (P/S)30.16
P/FCF Ratio-16.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.64Price Target Upside357.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.1
Revenue Forecast (FY)AU$27.40M
Argenica Therapeutics Ltd Business Overview & Revenue Model
Company Description
Argenica Therapeutics Limited engages in the research and development of a neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate use to protect brain cells and reduce cell death d...
How the Company Makes Money
Argenica Therapeutics Ltd primarily makes money through the development, commercialization, and potential licensing of its biopharmaceutical products, particularly ARG-007. The company's revenue model likely depends on securing partnerships with l...
Argenica Therapeutics Ltd Financial Statement Overview
Summary
Income Statement
26
Negative
Balance Sheet
62
Positive
Cash Flow
34
Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.21M | 2.60M | 0.00 | 259.10K | 296.07K |
| Gross Profit | 3.21M | 2.60M | 1.75M | 259.10K | 296.07K |
| EBITDA | 0.00 | -1.90M | -4.81M | -4.09M | -1.33M |
| Net Income | -7.17M | -5.48M | -4.82M | -4.09M | -1.03M |
Balance Sheet | |||||
| Total Assets | 11.04M | 16.38M | 9.54M | 9.04M | 7.27M |
| Cash, Cash Equivalents and Short-Term Investments | 10.56M | 15.91M | 9.34M | 8.91M | 7.14M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 3.80M | 2.43M | 1.87M | 735.91K | 425.72K |
| Stockholders Equity | 7.24M | 13.95M | 7.67M | 8.31M | 6.85M |
Cash Flow | |||||
| Free Cash Flow | -5.70M | -5.06M | -3.30M | -3.36M | -1.05M |
| Operating Cash Flow | -5.70M | -5.06M | -3.30M | -3.36M | -1.05M |
| Investing Cash Flow | 0.00 | 50.00K | -50.00K | 0.00 | 0.00 |
| Financing Cash Flow | 346.90K | 11.63M | 3.73M | 5.13M | 7.85M |
Argenica Therapeutics Ltd Technical Analysis
Negative
0.14
Price Trends
0.23
Negative
0.25
Negative
0.37
Negative
Market Momentum
-0.02
Positive
25.89
Positive
13.56
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:AGN, the sentiment is Negative. The current price of 0.14 is below the 20-day moving average (MA) of 0.18, below the 50-day MA of 0.23, and below the 200-day MA of 0.37, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 25.89 is Positive, neither overbought nor oversold. The STOCH value of 13.56 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:AGN.
Argenica Therapeutics Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | AU$499.34M | -29.29 | -47.44% | ― | ― | 67.26% | |
53 Neutral | AU$33.06M | -6.66 | -370.40% | ― | 306.88% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$18.63M | -2.48 | -183.51% | ― | ― | -5.68% | |
47 Neutral | AU$25.89M | -2.45 | -1964.93% | ― | -100.00% | 2.86% | |
44 Neutral | AU$10.20M | -0.48 | 1068.18% | ― | ― | 31.87% | |
41 Neutral | AU$108.75M | -2.12 | -30.19% | ― | ― | 63.46% |
* Healthcare Sector Average
AU:AGN
Argenica Therapeutics Ltd
0.15
-0.52
-78.03%
AU:ATH
Alterity Therapeutics
0.01
0.00
0.00%
AU:RAC
Race Oncology Ltd.
2.74
1.74
174.00%
AU:NC6
Nanollose Ltd.
0.08
0.04
120.59%
AU:AVE
Avecho Biotechnology Limited
0.01
0.00
0.00%
AU:1AD
AdAlta Ltd.
―
―
―
Argenica Therapeutics Ltd Corporate Events
Argenica boosts cash reserves with $3.97m R&D rebate to advance stroke drug
Mar 16, 2026
Argenica Therapeutics has received a $3.97 million cash rebate under the Australian Federal Government’s RD Tax Incentive Program for eligible research and development activities conducted in the 2025 financial year, including newly approved...
Argenica Widens Half-Year Loss as ARG-007 Stroke Trial Spending Climbs
Feb 10, 2026
Argenica Therapeutics reported a sharp increase in half-year loss to $3.8 million as it accelerated clinical and development spending on its neuroprotective drug pipeline. Revenue fell 77% to $720,169, primarily due to timing differences in recogn...
Argenica Wins EMA Paediatric Waiver, Streamlining EU Pathway for Stroke Drug ARG-007
Feb 1, 2026
Argenica Therapeutics has secured a full product-specific paediatric waiver from the European Medicines Agency for its lead neuroprotective candidate ARG-007 in acute ischaemic stroke, removing the obligation to conduct paediatric clinical trials ...
Argenica’s AI Analysis Confirms ARG-007 Efficacy in Severe Stroke, Paving Way for Phase 2b Trial
Jan 27, 2026
Argenica Therapeutics has reported new AI-driven post-hoc analysis from its Phase 2 acute ischaemic stroke trial showing statistically significant and clinically meaningful efficacy of its lead drug ARG-007 in patients with severe stroke, a group ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.